SLC5A2 and type 2 diabetes mellitus: Of clinical relevance, ZDF rats do respond to the majority of antidiabetic therapies including metformin (152), the GLP-1R agonist liraglutide (153), and the SGLT2 inhibitor empagliflozin (154), highlighting their utility as a translational model of T2D.